	US 11,857,567 B2
	Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
Qi-Ying Hu, Needham, MA (US); John Lee, Arlington, MA (US); and Fuxin Shi, Winchester, MA (US)
Assigned to Decibel Therapeutics, Inc., Boston, MA (US)
Filed by Decibel Therapeutics, Inc., Boston, MA (US)
Filed on Jun. 21, 2021, as Appl. No. 17/352,712.
Application 17/352,712 is a continuation of application No. 16/927,777, filed on Jul. 13, 2020, granted, now 11,071,751.
Application 16/927,777 is a continuation of application No. 16/517,284, filed on Jul. 19, 2019, granted, now 10,709,732, issued on Jul. 14, 2020.
Application 16/517,284 is a continuation of application No. PCT/US2019/017334, filed on Feb. 8, 2019.
Claims priority of provisional application 62/628,824, filed on Feb. 9, 2018.
Prior Publication US 2021/0308176 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/04 (2006.01); A61K 9/00 (2006.01); A61K 47/36 (2006.01)

CPC A61K 33/04 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0046 (2013.01); A61K 47/36 (2013.01)]

22 Claims

1. A hypertonic pharmaceutical composition having a calculated osmolarity of 3,000-7,000 mOsm/L and comprising 1M-2M of an anti-platinum chemoprotectant agent, a gelling agent, and an optional tonicity agent, wherein the calculated osmolarity is calculated based on the chemoprotectant agent and the tonicity agent, if present.